Nevro Corp. (NVRO)
$18.82
+1.50 (+8.66%)
Rating:
Recommendation:
Buy
| Symbol | NVRO |
|---|---|
| Price | $18.82 |
| Beta | 0.879 |
| Volume Avg. | 0.51M |
| Market Cap | 681.388M |
| Shares () | - |
| 52 Week Range | 13.98-46.71 |
| 1y Target Est | - |
| DCF Unlevered | NVRO DCF -> | |
|---|---|---|
| DCF Levered | NVRO LDCF -> | |
| ROE | -33.99% | Strong Sell |
| ROA | -18.24% | Sell |
| Operating Margin | - | |
| Debt / Equity | 67.88% | Buy |
| P/E | -6.56 | Strong Sell |
| P/B | 2.38 | Strong Buy |
Latest NVRO news
About
Download (Excel)Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.